• Research Use Only (RUO)
  • Free shipping on orders over $200
  • Expect 24 hours for order processing
  • Shipping days: Monday–Friday
  • Research Use Only (RUO)
  • Free shipping on orders over $200
  • Expect 24 hours for order processing
  • Shipping days: Monday–Friday

GLP-3 R 10MG

Categories:

Retatrutide is a research-grade multi-receptor agonist used in advanced metabolic studies. It enables investigation of glucose regulation, appetite signaling, and energy expenditure pathways. This peptide is widely utilized in obesity and metabolic disorder research models.

$100.00

- +
- +

Satisfaction Guaranteed

Secure
Payment

Third-party
Tested

⚠️ RESEARCH USE ONLY

This product is for R&D purposes only and is not approved for human or veterinary use.

Retatrutide 10mg – Triple Hormone Receptor Agonist for Metabolic Research

Quantum Biogenix offers research-grade Retatrutide, a novel multi-receptor agonist designed for advanced metabolic and endocrine research. Retatrutide targets GLP-1, GIP, and glucagon receptors, enabling comprehensive investigation of energy balance, glucose regulation, and metabolic signaling pathways in controlled laboratory environments.

By engaging multiple metabolic hormone receptors simultaneously, Retatrutide provides researchers with a unique tool to study coordinated metabolic responses. Experimental models associate multi-agonist activity with altered energy expenditure, appetite signaling, and glucose metabolism, positioning Retatrutide as a valuable compound in obesity and metabolic disorder research.

Product Name Retatrutide
Category Multi-Receptor Metabolic Research Peptide
Form Lyophilized Powder
Content 10mg
Purity ≥98% (HPLC Verified)
Application Metabolic, Endocrine & Energy Regulation Research
Usage Laboratory Research Only

Scientific Overview of Retatrutide

  • Triple agonist of GLP-1, GIP, and glucagon receptors
  • Modulates appetite, glucose metabolism, and energy expenditure
  • Supports investigation of integrated metabolic signaling
  • Used in obesity, diabetes, and metabolic disorder research models
  • High-purity peptide suitable for laboratory applications

Key Research Applications

  • Metabolic Disorder Studies – Evaluation of combined hormone receptor activation on metabolic balance.
  • Energy Expenditure Research – Investigation of thermogenesis and metabolic rate modulation.
  • Glucose Regulation Models – Analysis of insulin sensitivity and glucose homeostasis.
  • Appetite & Satiety Pathways – Study of central and peripheral appetite signaling mechanisms.
  • Obesity Research Models – Examination of multi-pathway metabolic intervention strategies.

Laboratory Handling & Storage

  • Form: Lyophilized research peptide
  • Purity: ≥98% (HPLC verified)
  • Recommended Storage: Store frozen or refrigerated, protected from light and moisture
  • Handling: Reconstitute using sterile laboratory-grade solvents
  • Stability: Maintain sealed and dry until research use

Mechanism of Research Interest

Retatrutide exerts its research significance through simultaneous activation of GLP-1, GIP, and glucagon receptors, creating a coordinated metabolic response across multiple signaling pathways. This multi-receptor engagement influences glucose utilization, lipid metabolism, appetite regulation, and energy expenditure. Experimental research models suggest that combined receptor activation may enhance metabolic efficiency and flexibility, making Retatrutide an advanced tool for studying complex metabolic systems.

Why Choose Quantum Biogenix?

  • High-purity, research-grade peptides
  • Batch-tested and quality-verified materials
  • Reliable sourcing and controlled manufacturing
  • Research-focused formulation standards
  • Secure laboratory supply chain handling

Research Use Only Notice

This product is supplied strictly for laboratory research use. It is not intended for human consumption, medical treatment, or veterinary application. Researchers must follow all institutional safety and experimental guidelines.

Scientific References

  1. Coskun T. et al. (2022). Triple-hormone-receptor agonists for metabolic disease. Nature Medicine.
  2. Jastreboff A.M. et al. (2023). Multi-agonist approaches to obesity treatment. New England Journal of Medicine.
  3. Müller T.D. et al. (2019). Glucagon and incretin receptor co-agonism. Molecular Metabolism.

Reviews

There are no reviews yet.

Be the first to review “GLP-3 R 10MG”

Your email address will not be published. Required fields are marked *

Scroll to Top
Age Verification!

*By continuing, you confirm eligibility and legal compliance.